Fladrafinil

Fladrafinil (CRL-40,941) is a bis(4-fluorinated) analogue of adrafinil, sharing the diphenylmethylsulfinylacetamide pharmacophore that defines the entire modafinil family. The N-hydroxyacetamide head group means it behaves as a hepatic prodrug — amidase cleavage in the liver liberates the corresponding modafinil-style metabolites that drive the actual wake-promoting and procognitive signal. The bis-fluorination is not cosmetic: it shifts potency roughly 3–4× higher than adrafinil and introduces a behavioural signature (serenic / anti-aggressive activity) that the parent compound lacks.

Dopamine Transporter Inhibition#

The dominant mechanism across the entire modafinil class is selective, low-affinity blockade of the dopamine transporter (DAT). Extracellular dopamine rises in the striatum and prefrontal cortex without the impulsive reinforcement profile of classical psychostimulants like amphetamine. This is the engine behind the focus, motivation, and time-on-task effects users report.

"Modafinil and its analogues all increase extracellular dopamine levels by blocking dopamine transporters (DAT), as well as activating hypothalamic wake-promoting nuclei (orexin and histamine), without typical psychostimulant adverse effects." — Hersey M, Tanda G. Advances in Pharmacology, 2024

Practically, this translates into the deep-work phenotype: extended attention, reduced subjective fatigue during cognitively demanding sessions, and a meaningful boost to long cardio blocks during a cut where motivation is the limiting factor.

Orexin and Histaminergic Wake Circuit Activation#

Downstream of the DA elevation, fladrafinil engages the hypothalamic wake-promoting nuclei — the orexin/hypocretin system in the lateral hypothalamus and the histaminergic tuberomammillary nucleus. This is the circuit that physiologically maintains arousal across the day, and it is the same circuit modafinil leverages. Activating it pharmacologically extends the wake state for 8–14 hours per dose and explains why late-day administration so reliably destroys sleep onset — the long half-life keeps these nuclei firing well past the intended cutoff.

Indirect Noradrenergic and Glutamatergic Tone#

Secondary contributions come from weak NET interaction, the downstream noradrenergic activation that follows DA elevation, and a shift in cortical excitation/inhibition balance — reduced GABA tone alongside elevated glutamate. The cognitive endpoint is the one bodybuilders and looksmaxxers actually care about: sharper working memory, faster task-switching, and the sympathetic edge useful for fasted cardio appetite suppression on a deficit.

"Modafinil and its derivatives, including adrafinil and related analogues, are associated with increased wakefulness, improved attention, and enhanced working memory, while chronic use is linked to tolerance and paradoxical cognitive decline." — Schifano F, Catalani V, Sharif S, et al. Drugs, 2022

The second half of that quote is the reason intermittent dosing (2–4 days/week) is community standard — chronic daily loading erodes the response and can flip the cognitive curve in the wrong direction.

Serenic (Anti-Aggressive) Activity Unique to Fladrafinil#

This is the one mechanism that genuinely separates fladrafinil from modafinil, adrafinil, and flmodafinil. The original Lafon Laboratories patent assays documented dose-dependent suppression of intraspecific aggression in mice — an effect that adrafinil itself essentially does not produce.

"Fladrafinil is notable for an antiaggressive effect that distinguishes it pharmacologically from adrafinil and modafinil, displaying a significant reduction in mouse fighting behavior in the original Lafon Laboratories patent assays." — Wikipedia contributors, 2024

The receptor-level basis for this is not fully characterised, but the practical implication is interesting: users running heavy androgen stacks who notice modafinil amplifies the "angry tunnel-vision" wakefulness sometimes report fladrafinil delivers the cognitive lift without the irritability spillover. Anecdotal at the human level, but mechanistically distinct from the rest of the class.

Hepatic Prodrug Activation#

The N-hydroxyacetamide structure means fladrafinil itself is largely inactive — hepatic amidase activity cleaves it toward the corresponding bisfluoro-modafinilic acid and, by analogy with the adrafinil → modafinil pathway, likely toward the active sulfinylacetamide flmodafinil (CRL-40,940). This loading on hepatic conjugation pathways is heavier than with modafinil itself, which is why community practice flags caution when fladrafinil is stacked with 17α-alkylated AAS or peak-dose isotretinoin. Periodic ALT/AST monitoring is appropriate during extended protocols, particularly when oral hepatotoxic compounds are in the stack. CYP3A4 induction is also class-typical — the practical consequence being reduced reliability of hormonal contraceptives in female subjects, which is the single most-overlooked interaction in the modafinil family.

Common (most users)#

• Insomnia / sleep displacement — the dose-limiting effect for almost everyone. The 12–16 h half-life is unforgiving of late dosing. Cut-off is ~10 hours before intended sleep; AM-only administration solves this for the vast majority of users.
• Headache — typically dehydration-mediated. Aggressive water + electrolyte intake (sodium, magnesium, potassium) through the dosing window resolves it. Adding 300–600 mg Alpha-GPC alongside the dose helps users who run cholinergic-deficit headaches on bare eugeroics.
• Mild appetite suppression — usually welcome in a cutting context, occasionally inconvenient on a maintenance or lean-bulk phase. Pre-loading a structured meal 30–45 min before dosing keeps caloric intake on track.
• Foul-smelling urine, mild dyspepsia, sulfurous taste — a benign signature of the sulfinyl group's metabolic breakdown, shared across the modafinil family. No mitigation needed; it's cosmetic.
• Mild tachycardia and a small resting BP bump — modest at 30–80 mg, additive with caffeine. Drop the caffeine stack or the dose if resting HR is climbing 15+ bpm above baseline.
• Jaw clenching / mild bruxism — dopaminergic in origin. Drops out with dose reduction; magnesium glycinate 400 mg in the evening helps.

Uncommon (dose-dependent or individual)#

• Anxiety, irritability, jitter — scales sharply above 100 mg. The fix is dose reduction, not stacking benzos or beta-blockers on top. L-theanine 200 mg with the dose blunts the edge without killing the wake effect.
• Anhedonic "comedown" the day after dosing — reported by users running fladrafinil more than 3–4 days per week. Tightening cycle cadence to 2 days per week restores baseline.
• Resting blood-pressure elevation — meaningful in users already running AAS, oral stimulants, or high-dose caffeine. Weekly resting BP checks during active dosing periods; back off if SBP creeps above 140 or DBP above 90.
• Hepatic enzyme elevation — the N-hydroxyacetamide prodrug structure loads hepatic conjugation pathways more heavily than modafinil itself. ALT/AST every 8–12 weeks is appropriate when fladrafinil is run regularly, and mandatory when co-administered with 17α-alkylated orals or peak-dose isotretinoin.
• Tolerance and paradoxical cognitive flattening — documented across the modafinil class with chronic use (Schifano et al. 2022).

"Modafinil and its derivatives, including adrafinil and related analogues, are associated with increased wakefulness, improved attention, and enhanced working memory, while chronic use is linked to tolerance and paradoxical cognitive decline." — Schifano et al., Drugs 2022

A 2-week washout after 6–8 weeks of intermittent dosing restores response.

Rare but serious#

• Severe cutaneous reactions (Stevens-Johnson syndrome, TEN, DRESS) — documented for modafinil and armodafinil and presumed class-wide. Any spreading rash, mucosal involvement, fever, or skin peeling is grounds for immediate discontinuation and emergency review. Non-negotiable.
• Significant hepatic injury — flagged by jaundice, dark urine, RUQ pain, or ALT/AST >3× ULN. Discontinue and re-assess; the N-hydroxyl loading is the rate-limiting concern, particularly in stacks containing other hepatotoxins.
• Cardiac arrhythmia or hypertensive crisis — uncommon at sensible doses but reported across the broader eugeroic/stimulant literature, particularly in stacks with sympathomimetics (clen, yohimbine, ephedrine, high-dose caffeine). Palpitations that don't resolve at rest, chest pain, or syncope = stop and seek review.
• Psychiatric events (mania, psychosis, suicidal ideation) — rare class effects of CNS stimulants and eugeroics. Personal or family history of bipolar disorder or psychotic illness materially raises risk.

Hard contraindications#

• Concurrent hormonal contraceptive use — the modafinil class induces CYP3A4 and reduces oral / transdermal / implant contraceptive efficacy. Non-hormonal contraception is required in female subjects throughout dosing and for at least one month after the final dose. This is the single most-overlooked interaction in the class.

"Modafinil and its analogues all increase extracellular dopamine levels by blocking dopamine transporters (DAT), as well as activating hypothalamic wake-promoting nuclei (orexin and histamine), without typical psychostimulant adverse effects." — Hersey & Tanda, Advances in Pharmacology 2024

• Concurrent MAOI use — hypertensive crisis risk via catecholamine potentiation. Hard line.
• Untreated hypertension or tachyarrhythmia — control BP and rhythm first, or pick a different cognitive enhancer.
• Severe hepatic impairment — the N-hydroxyacetamide prodrug pathway depends on functional hepatic conjugation. Not the compound for a compromised liver.
• Prior Stevens-Johnson syndrome, TEN, DRESS, or serious hypersensitivity to modafinil/armodafinil/adrafinil — class cross-reactivity is presumed.
• History of stimulant-precipitated mania or psychosis — the eugeroic class is implicated in the same precipitation pattern.

Gender-specific and ancillary notes#

Fladrafinil is not hormonally active. It does not aromatise, does not interact with the HPTA, does not virilise, and does not require PCT or anabolic ancillaries. The only sex-specific consideration is the CYP3A4 contraceptive interaction above — and it is non-trivial. Female subjects relying on hormonal contraception must switch to a non-hormonal method (copper IUD, barrier) for the duration of the protocol plus a one-month buffer.

For users stacking fladrafinil with hepatotoxic orals (17α-alkylated AAS, peak-dose isotretinoin), periodic ALT/AST is appropriate — not because fladrafinil alone is hepatotoxic at sensible doses, but because the N-hydroxyacetamide loading stacks on top of the oral's first-pass burden. Run TUDCA 500 mg/day in those configurations and pull bloods at the 8-week mark.

Used intermittently, weighed accurately, and cut off well before the sleep window, fladrafinil's side-effect profile is mild and manageable. The compounds that wreck the protocol are dosing precision, late-day administration, and treating it as a daily productivity drug.